Meta Information
ID:boswellia-serrata
Name:Boswellia Serrata
Schema Version:2.4_uniform_evidence_2026_06_18
Created
2026-07-02T07:04:55Z
Model
phase-b-newfiles-claude-opus-4.8
Interactions
Target id:
/class/nsaids
Target name:
NSAIDs / anti-inflammatories
Severity:
minor
Interaction type:
synergistic
Nature:
relative
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Boswellic acids inhibit 5-lipoxygenase and add to anti-inflammatory effects; generally complementary.
Actionable advice:
Usually well tolerated together; no specific harm expected.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Established mechanism / class pharmacology (no single primary source quoted)
Exact phrase from label:
Boswellia inhibits 5-LOX; complementary anti-inflammatory action. Mechanistic.
Label source:
Class inference
Action type:
informational_none
Target id:
/class/cyp3a4-substrates
Target name:
CYP3A4 substrates
Severity:
minor
Interaction type:
pharmacokinetic
Nature:
relative
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Boswellia extracts may modestly affect CYP3A4 in vitro, with unclear clinical relevance.
Actionable advice:
Low clinical significance; monitor if taking narrow-therapeutic-index CYP3A4 drugs.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Established mechanism / class pharmacology (no single primary source quoted)
Exact phrase from label:
Boswellia shows in-vitro CYP modulation; uncertain clinical impact. Low-certainty.
Label source:
Class inference
Action type:
informational_none